Publications by authors named "M Bressel"
Article Synopsis
- - The study investigates the expression of BCL-2 family proteins in nasopharyngeal carcinoma (NPC) tumors and evaluates the effectiveness of BH3 mimetics, particularly their combination with cisplatin, for cancer treatment.
- - Results showed that BCL-2 was more commonly expressed in Epstein-Barr virus (EBV)-positive NPC tumors, but this expression did not predict overall survival outcomes.
- - The combination treatment using S63845 and cisplatin exhibited significant anticancer effects in specific NPC cell lines, indicating potential for further research in this therapeutic approach.
Article Synopsis
- Lutetium-177 [Lu]Lu-PSMA-617 is being studied for its effectiveness in improving survival and quality of life for patients with metastatic castration-resistant prostate cancer, but its benefits for hormone-sensitive prostate cancer are still unclear.
- The UpFrontPSMA trial involved patients with high-volume metastatic hormone-sensitive prostate cancer, who were randomly assigned to receive either [Lu]Lu-PSMA-617 followed by docetaxel or docetaxel alone as standard care.
- The primary goal of the trial was to determine if patients treated with [Lu]Lu-PSMA-617 could achieve undetectable levels of prostate-specific antigen (PSA) after 48 weeks.
Article Synopsis
- Stereotactic radiotherapy (SRT) is being tested as a treatment for choroidal melanoma (CM) located near the optic nerve, with a focus on preserving vision while maintaining survival rates.
- The study involved 20 patients and monitored outcomes like metastasis-free survival and visual acuity over a median follow-up of 5.1 years, with promising results showing high rates of both metrics.
- Findings suggest that meaningful vision was preserved in a significant portion of patients, and the reduced-dose SRT approach is worth further exploration.
In the phase 2 clinical trial (AIM) of venetoclax-ibrutinib, 24 patients with mantle cell lymphoma (MCL; 23 with relapsed/refractory [R/R] disease) received ibrutinib 560 mg and venetoclax 400 mg both once daily. High complete remission (CR) and measurable residual disease negative (MRD-negative) CR rates were previously reported. With median survivor follow-up now exceeding 7 years, we report long-term results.
View Article and Find Full Text PDFBackground: Older patients are often underrepresented in clinical trials owing to exclusionary comorbidities, which are more common with age. Chemotherapy is poorly tolerated in older comorbid advanced cutaneous squamous cell carcinoma (CSCC) patients; however, little is known on the efficacy and tolerability of immune-checkpoint inhibitors (ICIs) in this population. To our knowledge, this is the largest dedicated report on a cohort of older patients with advanced CSCC treated with immunotherapy to date.
View Article and Find Full Text PDF